from the University of Nevada School of Medicine followed by a residency in internal medicine at the University of Washington School of Medicine and a medical oncology fellowship at the National Cancer Institute.
Food and Drug Administration and National Institutes of Health.ĭr. Prior to his industry career, he held leadership positions at the U.S. Bishop was Senior Vice President Hematology / Oncology at Gilead Sciences and held clinical development roles at Genentech, Johnson & Johnson and Sanofi-Aventis. Before founding aratinga.bio in 2017, Dr. Previously, he was Executive Vice President and CMO at aratinga.bio, a developer of novel cancer immunotherapies. Bishop was the CMO of Clover Biopharmaceuticals, a global biotech company focused on the development of vaccines and biologics. Bishop is an experienced executive and medical oncologist with extensive experience in cancer drug development. He has also held senior marketing and sales positions at Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhône-Poulenc Rorer Pharmaceuticals and Schering-Plough Corporation. Orwin was Senior Vice President of the BioOncology Business Unit at Genentech (now a member of the Roche Group), where he was responsible for all marketing, sales, business unit operations and pipeline brand management for Genentech’s oncology portfolio in the United States. Prior to Relypsa, he served as Chief Executive Officer and a member of the Board of Directors of Affymax. Orwin’s tenure at Relypsa, the company launched and commercialized its lead candidate, Patiromer (US brand name Veltassa®), and was acquired by Galenica (Vifor Pharma) in a transaction worth over $1.5 billion. Orwin brings over 25 years of diverse experience in the biotechnology and pharmaceutical industries, having held senior positions at leading pharmaceutical and biotechnology companies, including Johnson & Johnson, Affymax, Rhone-Poulenc Rorer, Genentech, and most recently Relypsa.
0 kommentar(er)
